BioSpace News Archive

- Multiple key data read-outs expected for 2021, including the ARC-7 interim analysis in 2Q21 - Domvanalimab’s advancement into a registrational study coupled with recent IND clearance for AB308, Arcus’s FcR-enabled anti-TIGIT antibody, reinforces Arcus’s position as a leader in the anti-TIGIT field - Promising early data in first-line metastatic pancreatic cancer for AB680, the first small-molecule CD73 inhibitor to enter clinical development,

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at two upcoming virtual investor conferences:

Researchers at University of Texas, Galveston, in collaboration with Cell Science Systems, Corp., recently reported in the British Journal of Gastroenterology, results of a one-year weight loss study. The

PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study evaluating Evrysdi™ (risdiplam) in infants with symptomatic type 1 spinal muscular atrophy (SMA) in The New England Journal of Medicine (NEJM).

BrainChip Holdings Ltd, a leading provider of ultra-low power high performance artificial intelligence technology, announced progress in testing with the NaNose where patients’ exhaled breath samples were tested for COVID-19.

World’s largest AIDS group urges administration to also deploy Ryan White clinics as vaccination sites to better reach ambitious and lifesaving target

DENTSPLY SIRONA Inc., announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share of common stock, an indicated annual rate of $0.40 per share.

Isleworth Healthcare Acquisition Corp. (NASDAQ: ISLEU) (the “Company”) announced today that it priced its initial public offering of 18,000,000 units at a price to the public of $10.00 per unit.

The NantKwest Special Committee and the NantKwest Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 8, 2021 at 9:30 a.m. Pacific Time

Halozyme Therapeutics, Inc., a leader in converting IV biologics to subcutaneous delivery, announced the pricing of $700 million aggregate principal amount of its convertible senior notes due 2027.